The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

ABSTRACT:

SUBMITTER: Golay J 

PROVIDER: S-EPMC5622871 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature